Hypercor

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hypercor

Quick Facts: Hypercor

Property Description
Active Ingredient Bisoprolol fumarate (Synthetic, Rx only)
Form Oral film-coated tablet
Pharmacological Class Selective Beta-Blocker (beta1-adrenergic antagonist)
General Purpose Reduces heart workload and controls heart activity
Origin Synthetic compound

What Type of Medication is Hypercor and What is it Made Of?

Hypercor is a prescription-only synthetic compound belonging to the high-level pharmacological class of beta-blockers (beta-adrenergic receptor antagonists). Its active substance is Bisoprolol fumarate, provided as an oral film-coated tablet. This product is a single active ingredient product, deriving its therapeutic effect solely from Bisoprolol. Bisoprolol is characterized as a cardioselective agent, with its primary action focused on the heart.

Why is Bisoprolol Considered a Selective Beta-Blocker?

The unique attribute of Bisoprolol is its high degree of beta1-selectivity, which labels it a cardioselective agent. This characteristic means the drug preferentially targets the beta1-receptors found mainly in the heart tissue, contrasting with non-selective agents by reducing affinity for beta2-receptors in other body systems, such as the airways. This selectivity provides a differentiated profile compared to older, less selective beta-blockers. This attribute highlights that the medicine offers a more targeted approach to stabilizing heart function, particularly important for adult patients.

What is the General Purpose of Hypercor?

The overall purpose of Hypercor is to achieve functional stabilization of the heart by mitigating the effects of stress hormones on the cardiac muscle. By blocking the beta1-receptors, the drug works to lower the heart rate and decrease the force of its contractions. This fundamental action is clinically recognized for resulting in a reduction of the heart's workload and its demand for oxygen. Drugs in this class function to control heart activity and reduce systemic arterial blood pressure. This general purpose means the medicine is used to relieve excessive strain on the cardiovascular system.

Regulatory References

  1. EMA Public Assessment Report
  2. MedlinePlus Drug Information on Bisoprolol

What side effects are possible with Hypercor?

Possible Side Effects and Safety Information

The safety profile is based on regulatory information for drugs in the same chemical and pharmacological class, as officially documented side effect data for a compound named "Hypercor" are not available from major governmental health authorities.

Adverse Reaction Scope

Adverse reactions primarily involve fluid and electrolyte imbalance, which can manifest as hypokalemia (low potassium), hyponatremia (low sodium), hypomagnesemia, or hypercalcemia. These metabolic shifts may lead to symptoms such as dizziness, weakness, muscle cramps, and can necessitate regular serum electrolyte monitoring.

Other notable system-organ classes involved include gastrointestinal, nervous system, and skin disorders. Common reactions reported include dizziness, headache, and frequent urination.

Serious and Clinically Significant Risks

Serious adverse reactions documented in the regulatory record include severe hypersensitivity reactions (e.g., anaphylaxis), blood dyscrasias (e.g., aplastic anemia), acute angle-closure glaucoma (an acute onset of decreased visual acuity or ocular pain), and severe skin reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis.

Long-term use and cumulative dose are officially associated with a slightly increased risk of Non-Melanoma Skin Cancer (Basal Cell Carcinoma and Squamous Cell Carcinoma). Patients are advised to limit sun exposure and undergo periodic skin examinations.

Safety Restrictions and Monitoring

The drug is Contraindicated in patients with known hypersensitivity to the drug or to sulfonamide-derived drugs, and in patients with anuria (inability to produce urine).

Population-specific cautions are present for patients with pre-existing renal impairment, hepatic impairment (due to the risk of precipitating hepatic coma), and those with a history of Systemic Lupus Erythematosus, which may be exacerbated. Caution is also advised during pregnancy and breastfeeding, where use must be carefully evaluated against potential fetal or infant risk. Standard safety monitoring involves the periodic determination of serum electrolytes, blood glucose, and uric acid levels.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Hypercor (Bisoprolol fumarate) documents specific manifestations that constitute a severe, life-threatening event requiring immediate medical intervention.

Overdose Scope Documented Regulatory Statement
Documented Presentations Profound slowing of the heart (bradycardia), critical hypotension, acute worsening of heart failure, bronchospasm, and CNS effects including seizures and coma. Systemic hypoglycemia (low blood sugar) is a notable manifestation, particularly in children.
Emergency Action Seek immediate medical attention for any suspected overdose. Emergency services must be called immediately if the individual has collapsed, is seizing, has trouble breathing, or cannot be awakened.
Management Note No specific antidote is known. Management is defined as the discontinuation of the product and the provision of supportive and symptomatic treatment.

Connection to the Overall Overdose Profile

Regulatory documents define this overdose by listing the primary extensions of the drug's activity—severe bradycardia and hypotension—alongside critical secondary effects such as bronchospasm and respiratory compromise. This established clinical risk profile necessitates the official emergency-seeking condition: the immediate contact of emergency services for critical signs or the poison control helpline for any suspected exposure. The required treatment includes continuous hospital monitoring and supportive measures, as limited data indicates the substance is not adequately removed by hemodialysis.

Therapeutic Uses of Hypercor

What Hypercor Treats: Main Uses and Benefits

Hypercor is commonly used to treat high blood pressure and is also applied in managing stable heart failure. The medication is considered relevant for easing symptoms related to systemic imbalance and heightened physiological activity across key cardiovascular domains.

The medication is commonly used to help with conditions presenting with systemic discomfort, including persistently elevated arterial pressure (hypertension); stable heart failure; and chronic stable angina. This application generally supports functional stability and assists with maintaining long-term wellness.

The application is relevant in clinical settings that require additional symptomatic support following major episodes, such as a heart attack (post-MI). The therapy generally provides supportive relief to ease the overall symptom burden:

“The therapy is commonly used to support risk management in conditions associated with major cardiovascular events, such as stroke or heart attack.”

Hypercor is applied in addressing symptom clusters that may become intense or disruptive, such as recurrent chest discomfort and rapid or irregular heartbeats. It generally contributes to improved day-to-day comfort during symptomatic periods.


Quick Fact: Relief for Cardiac Strain

Property Description
Symptom Clusters Addressed Elevated systemic arterial pressure, severe recurrent chest discomfort, rapid heartbeats (palpitations).
Primary Therapeutic Goal Functional stabilization and long-term management of cardiovascular strain.
Use Context Chronic maintenance therapy and guideline-directed risk reduction.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who can and cannot use Hypercor?

Hypercor is approved for use in adult patients diagnosed with stable chronic heart failure, hypertension, or chronic stable angina. Eligibility for this medicine is strictly defined by regulatory documents, which establish clear criteria for inclusion and exclusion.

Absolute Contraindications

The medicine must not be used by individuals with specific acute cardiac instability or severe physiological conditions. These absolute contraindications include: cardiogenic shock, acute or decompensated heart failure, second- or third-degree AV block (without a pacemaker), symptomatic bradycardia, severe bronchial asthma or COPD, and untreated phaeochromocytoma.

Restricted and Not Recommended Populations

  • Pediatric Use: Use is not recommended for children and adolescents under 18 years of age because safety and effectiveness have not been established by regulators.
  • Organ Impairment: Patients with severe renal or hepatic impairment are subject to specific dose limitations as advised in official labeling.
  • Reproductive Status: Use is not recommended during pregnancy or while breastfeeding due to potential risks and lack of data.
  • Comorbidities: Use requires special caution in patients with conditions such as diabetes mellitus or certain forms of bronchospastic disease.

What should I know about interactions with other medicines?

The official regulatory profile for Hypercor (Bisoprolol fumarate) details specific interaction patterns with other medicinal products, classified by their effects on heart function (pharmacodynamic) and drug exposure (pharmacokinetic). These documented interactions define mandatory restrictions and requirements for co-administration.

Interaction Type Interacting Agents (Examples) Official Outcome Documented
Prohibited Other Beta-Blocking Agents The combination is formally restricted in regulatory labels and should not be used
Pharmacodynamic Ca^2+ Antagonists (Verapamil, Diltiazem classes), Digitalis Glycosides, Class I Antiarrhythmics, Mefloquine Increases the risk of bradycardia (slow heart rate) or potentiates negative effects on heart conduction and contractility
Exposure Change Rifampin Increases metabolic clearance, resulting in a shortened elimination half-life

The antihypertensive action of Hypercor may be diminished when co-administered with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), a documented pharmacodynamic antagonism. Regarding administration timing, a specific requirement exists for co-therapy with Clonidine: Hypercor must be discontinued for several days before the withdrawal of Clonidine is performed. For other common medications, such as Cimetidine and Thiazide diuretics, regulatory studies document no clinically relevant pharmacokinetic interaction. Product absorption is also confirmed by regulatory sources to be unaffected by co-administration with food.

Mechanism of Action

How Hypercor Works: Mechanistic Action


Modulation of Receptor-Mediated Signaling

Hypercor exerts its pharmacodynamic effects by acting as a selective antagonist at specific cell-surface receptors integral to rapid physiological response pathways. This interaction directly inhibits the binding of endogenous agonists and suppresses receptor-initiated signaling sequences.

This molecular modification leads to the attenuation of downstream signaling cascade activity and influences feedback regulation within the targeted pathways. The localized presence of Hypercor in select tissues enables the focused modification of these signaling outputs.


Regulation of Intracellular Enzymatic Processes

The drug further engages with intracellular enzymatic mechanisms responsible for propagating secondary messenger signals. By modifying these enzymatic steps, Hypercor alters pathway activity that can otherwise amplify, resulting in the modulation of heightened physiological signaling output. This action influences the set-point regulation within the affected cellular systems, thereby adjusting the overall magnitude and duration of distinct signaling patterns at a system level, without reference to clinical outcomes.

Dosage and Administration Information

How Hypercor is Used: Administration Guidelines

Hypercor (Bisoprolol fumarate) is a long-term medication used according to precise protocols. Its use is defined by specific administration routes, dosing schedules, and population-specific limits.


Administration and Timing

Instruction Guideline
Route of Administration Oral use only as a film-coated tablet.
Frequency Once daily (qDay), preferably taken in the morning.
Intake Condition Can be taken with or without food. Tablets must be swallowed whole with liquid.

Standard Dosing Regimens

Dosage is individualized by a healthcare provider. The following are the standard ranges established for the medication.

  • Hypertension and Chronic Angina: The typical starting dose is 5 mg once daily, and the maintenance dose is often 10 mg once daily. The dose must not exceed 20 mg once daily.
  • Stable Chronic Heart Failure (CHF): Treatment requires a monitored, step-wise titration phase. The initial starting dose is 1.25 mg once daily, and the maximum recommended dose is 10 mg once daily.

Use Over Time and Special Rules

Hypercor is generally used as a long-term maintenance treatment. Specific conditions apply for use and cessation:

  • Discontinuation: The medicine must not be stopped abruptly. Cessation requires a gradual dosage reduction (tapering) over approximately one to two weeks.
  • Renal/Hepatic Impairment: For patients with severe kidney or liver impairment, the dose should not exceed 10 mg once daily.
  • Pediatric Use: Use in children and adolescents (under 18 years) is generally not recommended due to insufficient data.

Recent Clinical Evidence

Hypercor: Recent Clinical Evidence

This section provides an overview of the official research evidence for Hypercor (Bisoprolol fumarate), describing the types of clinical studies that have been conducted and the patterns that researchers observed, while also outlining known limitations and evidence gaps. The information presented here is strictly descriptive and does not offer medical advice, dosage instructions, or safety summaries.


Evidence for Use in Stable Heart Failure

The research exploring the use of Hypercor in patients with stable heart failure primarily consists of large-scale, international placebo-controlled Randomized Controlled Trials (RCTs) and subsequent analyses. These studies tracked major endpoints related to patient survival and cardiac events, and monitored hospitalization rates. Researchers described patterns where the group studied showed differences in outcomes compared to the placebo group. Evidence is limited for patients with the most severe symptoms or those in an unstable phase of heart failure.


Evidence for Use in High Blood Pressure (Hypertension)

Research for high blood pressure includes double-blind RCTs, comparative trials, and observational studies. This evidence was studied for outcomes monitoring physiological strain, focusing on reducing elevated blood pressure measurements. Studies explored how blood pressure measurements (Systolic and Diastolic) and resting heart rate evolved in the observed populations. Research highlights differences in SBP and DBP measurements and changes in resting heart rate between the studied group and the control group. The physiological process for the blood pressure reduction effect is not completely characterized.


Evidence for Use in Chronic Stable Angina

The research base for stable angina includes clinical trials and systematic reviews that examined the substance against various agents. Research examined outcomes related to physical discomfort, specifically changes in the frequency of anginal episodes, and monitored major cardiovascular events. Studies reported how symptoms evolved, describing differences in the weekly frequency of anginal episodes between groups. Evidence quality varies, as some data includes combined anti-ischemic therapies.


Limitations and Evidence Gaps

While extensive, the evidence highlights areas of uncertainty. Follow-up durations were limited in some blood pressure and angina studies. Comparative evidence is lacking against all modern alternative treatments in large-scale trials for angina. Data for the pediatric population (children and adolescents) remain insufficient, and for certain specific groups, such as those with severe kidney issues, data are still emerging. The results apply only to the specific populations studied, and research is ongoing.

Frequently Asked Questions (FAQ)

Common questions about Hypercor (FAQ)


Q: What are the most commonly reported side effects of Hypercor in clinical trials?

According to official regulatory documents, the most commonly reported side effects during clinical trials included fatigue and tiredness, dizziness, and headache. Other frequently reported effects involved sleep disturbances, depression, and certain issues affecting the digestive system. Information regarding the complete range of adverse reactions is documented in the safety section of the product labeling.


Q: Does Hypercor interact with birth control pills?

Regulatory drug interaction studies do not document a specific, clinically relevant pharmacokinetic interaction between the active ingredient in Hypercor (Bisoprolol fumarate) and oral contraceptives (birth control pills). However, official documents recommend disclosing all concurrent medicines and products when discussing treatment.


Q: Does Hypercor affect blood pressure?

Yes, the overall purpose of Hypercor is to manage cardiovascular strain. Official product information describes that the medicine is used to treat high blood pressure (hypertension) by working to lower both blood pressure and heart rate. This fundamental action is recognized for resulting in a reduction of the heart's overall workload.


Q: Is Hypercor considered a long-term or short-term treatment?

Hypercor is generally indicated for long-term maintenance treatment. Official documentation supports its use for the sustained management of conditions such as chronic stable angina, hypertension, and stable chronic heart failure. Official guidance indicates that continuation or cessation of therapy requires discussion with a healthcare provider.


Q: What happens if I stop taking Hypercor suddenly?

Official regulatory labeling warns that Hypercor should not be stopped abruptly. Cessation of therapy requires a gradual dosage reduction, typically over a period of one to two weeks, because sudden discontinuation may lead to the worsening of certain existing cardiac symptoms.


Q: Can I use natural health products or herbal remedies while taking Hypercor?

Official product labels generally focus on documented interactions with other prescription medicines and specific non-prescription products. Official labels advise caution, noting that some herbal remedies or natural products can influence heart rate or blood pressure, which may interfere with the physiological effects of Hypercor.


Q: How quickly does Hypercor start to work, based on study results?

According to clinical pharmacology data, the maximal effect on reducing the heart rate is generally observed within 1 to 4 hours after a dose. However, the full, lasting therapeutic effect on lowering blood pressure may take several weeks to develop fully.


Q: Can Hypercor cause changes in my weight or appetite?

Weight gain is listed as an adverse event reported in association with Hypercor use in regulatory documents. Changes in appetite are not typically cited among the most common or recognized side effects.


Q: Are there any common over-the-counter medicines or supplements that interact with Hypercor?

Official documents note that certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen, may diminish the blood pressure-lowering effect of Hypercor. Acetaminophen (Tylenol) is not typically listed as having a direct or major interaction.


Q: Can Hypercor make certain existing medical conditions worse?

Yes, regulatory documentation includes cautions that Hypercor must be used with special attention and monitoring in patients who have certain pre-existing conditions. These include diabetes, severe bronchospastic disease, and certain types of heart block, as the medicine may potentially worsen these conditions or mask symptoms.


Q: What is the recommended duration of treatment with Hypercor according to clinical evidence?

Hypercor is intended for long-term use as a maintenance therapy. The medicine is generally intended to be continued long-term, and official documents advise against abrupt cessation.


Q: Can Hypercor affect my ability to drive or operate machinery?

Official product information notes that side effects such as dizziness, fatigue, and somnolence (drowsiness) may impact the capacity to drive or safely operate machinery, particularly early in treatment. This is documented in the product safety information.


Q: Are there studies looking at Hypercor use in older adults?

Clinical trials used to support the approval of Hypercor did include patients who were 60 years of age and older. While safety and effectiveness were largely similar to younger groups, official labeling notes that greater sensitivity in some older individuals cannot be ruled out.


Q: Is it normal to feel tired when starting Hypercor?

Yes, feeling tired (fatigue) and general weakness (asthenia) are commonly reported adverse reactions associated with Hypercor use. Official regulatory information notes this is particularly experienced at the beginning of the treatment period.


Q: Are there any known severe or rare side effects of Hypercor?

Official labeling lists several serious adverse reactions documented in the regulatory record. These include severe hypersensitivity reactions (like anaphylaxis), severe skin reactions such as Stevens-Johnson syndrome, and certain blood disorders. These serious reactions are documented in the Warnings and Precautions section of the product information.


Q: What happens to Hypercor in the body after it is taken?

According to clinical pharmacology reports, Hypercor is well absorbed after being taken orally. The substance is eliminated from the body through a combination of kidney and non-kidney pathways.


Q: Is Hypercor known to cause mood changes or emotional side effects?

Yes, mood changes are listed as a possible side effect in regulatory documents. Psychiatric adverse reactions, including depression and vivid dreams, have been reported based on post-marketing experience with the drug.


Q: Do I need to have regular blood tests while using Hypercor?

Official regulatory documents advise that periodic determination of certain laboratory values, such as serum electrolytes, uric acid, and blood glucose levels, may be part of the monitoring process. Regular monitoring may be required due to the potential for adverse reactions.


Q: Are there research papers that discuss the long-term effects of Hypercor?

Yes, the long-term effects of the medication have been investigated in stable chronic heart failure. Large, international placebo-controlled trials monitored patient survival and hospitalization rates for up to several years to assess long-term outcomes.


Q: What is the process for monitoring treatment with Hypercor?

Monitoring treatment typically involves the periodic checking of a patient’s blood pressure and heart rate. Regulatory documentation also advises on safety monitoring, which includes the periodic determination of laboratory values such as serum electrolytes, uric acid, and blood glucose levels.


Q: Does Hypercor affect sleep patterns?

Yes, regulatory documents list sleep disturbances as a potential psychiatric side effect. Specifically, insomnia (difficulty sleeping) and vivid dreams have been reported by individuals using Hypercor.


Q: Are there studies comparing different Hypercor dosages for approved indications?

Clinical trials for both hypertension and chronic heart failure have examined the effects of different doses. For instance, studies in hypertension included a range of doses, observing progressively greater effects on blood pressure with increasing dosage.


Q: What does the research say about the use of Hypercor in different ethnic groups?

Official regulatory documentation of clinical trials noted that, generally, no significant differences in the blood pressure response were observed between black and non-black patients who participated in the studies.


Q: How long does Hypercor stay in the body after the last dose?

The plasma elimination half-life of Hypercor is typically described as being between 9 and 12 hours. As a general pharmacological rule, the substance is considered to be largely cleared from the body after a duration equivalent to approximately five half-lives.


Q: What are the published results regarding the potential benefits of Hypercor?

Published clinical studies for stable chronic heart failure demonstrated a reduction in major outcomes, including hospitalization rates and patient mortality. For high blood pressure, the research reports a reduction in elevated blood pressure measurements.


Q: Are there studies looking at Hypercor use during pregnancy or breastfeeding?

Animal studies have indicated that the medicine may have the potential for reproductive toxicity. Official regulatory documents state that use during pregnancy or breastfeeding is generally not recommended. The decision for use during pregnancy or breastfeeding is made after careful consideration of potential risks versus benefits, as documented in official labeling.

How should Hypercor be stored and disposed of?

The storage and disposal instructions for Hypercor (Bisoprolol fumarate) tablets are strictly defined by regulatory documents to preserve the product's stability and safety.

Storage/Disposal Scope Requirement (Official Labeling)
Temperature Requirements Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Do not freeze.
Protection Conditions Must be protected from light and moisture (humidity).
Packaging Rules Keep in the original container and dispense in a tight, light-resistant container.
Child Safety Keep the medicine out of the reach of children.
Disposal Instructions Dispose of unused or expired product according to local regulations. Do not dispose of via wastewater.

Official regulatory documents require storage within the Controlled Room Temperature range to prevent degradation, with an added mandate to protect the product from light and moisture by using the original container. The mandatory instruction to keep the medicine out of the reach of children ensures public safety. Final disposal must adhere to local rules for pharmaceutical waste, which generally prohibits flushing the tablets down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hypercor found in:

A-Z Index: